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RAC3 influences the chemoresistance 
of colon cancer cells through autophagy 
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Abstract 
Background: RAC3 coactivator overexpression has been implicated in tumorigenesis, contributing to inhibition of 
apoptosis and autophagy. Both mechanisms are involved in resistance to treatment with chemotherapeutic agents. 
The aim of this study was to investigate its role in chemoresistance of colorectal cancer.
Methods: The sensitivity to 5-fluorouracil and oxaliplatin in colon cancer cells HT-29, HCT 116 and Lovo cell lines, 
expressing high or low natural levels of RAC3, was investigated using viability assays.
Results: In HCT 116 cells, we found that although 5-fluorouracil was a poor inducer of apoptosis, autophagy was 
strongly induced, while oxaliplatin has shown a similar ability to induce both of them. However, in HCT 116 cells 
expressing a short hairpin RNA for RAC3, we found an increased sensitivity to both drugs if it is compared with control 
cells. 5-Fluorouracil and oxaliplatin treatment lead to an enhanced caspase 3-dependent apoptosis and produce an 
increase of autophagy. In addition, both process have shown to be trigged faster than in control cells, starting earlier 
after stimulation.
Conclusions: Our results suggest that RAC3 expression levels influence the sensitivity to chemotherapeutic drugs. 
Therefore, the knowledge of RAC3 expression levels in tumoral samples could be an important contribution to design 
new improved therapeutic strategies in the future.
Keywords: Colorectal cancer, RAC3, Chemoresistance, Apoptosis, Autophagy
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Colorectal cancer (CRC) is one of the most commonly 
diagnosed cancers, and 1.23 million patients are diag-
nosed with CRC worldwide each year [1]. Despite recent 
advances in chemotherapies that have improved survival 
rates, patients with late-stage disease and elderly [2] still 
have a poor prognosis, and the overall mortality rate of 
CRC is approximately 40% [3–5].
Although CRC has been widely studied and the role 
of cancer stem cells in the persistence and expansion of 
this disease shows to be central, the genetic changes and 
molecular mechanisms underlying the development and 
progression of this cancer are not completely understood 
[6–11].
In CRC, chromosomal aberrations have been exten-
sively analyzed by comparative genomic hybridization, 
and several frequently amplified regions, including 20q, 
have been identified [12]. Amplification of 20q has been 
also detected frequently in many other cancers, like 
breast, ovarian, gastric, bladder, and hepatocellular can-
cers [13, 14]. Amplification and overexpression of an 
oncogene have been shown to play an important role in 
the pathogenesis of various cancers, probably because 
overexpression of the amplified oncogene confers a 
growth advantage. Several candidate oncogenes have 
been isolated from 20q, including AIB1 at 20q12 [15].
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Amplified in breast cancer 1 (AIB1), also known 
as Receptor associated-coactivator 3 (RAC3, SRC-3, 
ACTR, TRAM2, pCIP and NCoA3), is a member of the 
SRC/p160 coactivator family that also includes SRC-1 
(NCoA1) and SRC-2 (GRIP1, TIF2 and NCoA2) [16]. 
RAC3 is highly expressed in several human cancers 
such as breast cancer [15], prostate cancer [17] and liver 
cancer [18, 19] and has been demonstrated to be a key 
regulator in tumor initiation, progression, metastasis 
and survival [18, 20, 21]. RAC3 can interact with nuclear 
receptors and other transcription factors to regulate the 
expression of their target genes involved in many signal-
ing pathways, including ERα, E2F1, NF-κB and HER2/
neu [21–24]. It has been reported that RAC3 is overex-
pressed in 35% of human CRC samples [25]; however, the 
role of RAC3 in CRC progression is still unknown.
We have previously found that RAC3 overexpression 
has an anti-apoptotic and anti-autophagic role [26–28], 
not only through its nuclear action, but also by positively 
regulating the activity of p38 and Akt kinases, inhibit-
ing caspase-8 and -9 and blocking apoptosis-inducing 
factor-1 (AIF-1) translocation from mitochondria to the 
nucleus [27].
In this study we investigated the effect of RAC3 expres-
sion levels in the sensitivity to several chemotherapeu-
tic drugs. We found that expression of this oncogene is 
significantly higher in some CRC cell lines. Interestingly, 
the sensitivity to chemotherapy treatments could be 
effectively improved by decreasing RAC3 expression and 
increasing the apoptotic and autophagic responses.
Methods
Patients and tissue specimens
CRC specimens tissues (n  =  14) and normal tissue 
(n = 3) (Table 1) were obtained from Instituto de Inves-
tigaciones Médicas Dr. A. Lanari FMED-UBA, Buenos 
Aires, Argentina. All samples were confirmed by patho-
logical examination, and staging was performed accord-
ing to the 1997 CRC staging system of the UICC. Among 
the 14 CRC samples, 5 were from male patients and 9 
were from female patients, with ages ranging from 68 
to 91  years (median, 81.1  years). Informed consent was 
obtained from all patients, and this study was approved 
by the ethics committee of Instituto de Investigaciones 
Médicas Dr. A. Lanari.
Immunohistochemical staining
Paraffin-embedded tissue blocks were sectioned, depar-
affinized in xylene and rehydrated for immunohisto-
chemical staining [28]. Antigen retrieval was performed 
using sodium citrate. The sections were then incu-
bated in  H2O2 (3%) for 10 min, blocked in horse serum 
for 60  min and incubated with an anti-RAC3 antibody 
(Santa Cruz Biotechology, 1:100) at 4 °C overnight. After 
incubation with a universal biotinylated secondary anti-
body for 60  min, the specimens were incubated with 
 H2O2-diaminobenzidine (DAB) until the desired staining 
intensity was observed. The sections were counterstained 
with hematoxylin, dehydrated and mounted.
Cell culture and reagents
Human CRC cell lines HT-29  (ATCC® HTB-38™), HCT 
116  (ATCC® CCL-247™) and LoVo  (ATCC® CCL-229™) 
were purchased from American Type Culture Collection 
 (ATCC® Manassas, VA, USA). All cells were maintained 
in DMEM/F12 (Invitrogen Corp., USA) supplemented 
with 10% fetal bovine serum (FBS) (Invitrogen Corp., 
USA) and cells were incubated at 37  °C in a humidified 
incubator containing 5%  CO2.
Unless stated, reagents were obtained from Sigma 
Chemical Co. (St Louis, MO), Thermo Fisher Scientific 
(Waltham, MA) or Santa Cruz Biotechnology, USA.
Plasmid construction and transfection
The short hairpin RNA (shRNA) target sequence for 
RAC3 (shRAC3) and scramble (control) were previously 
Table 1 The correlation of RAC3 expression levels and clin-
ical-pathological features in CRC
a correspond to 3 female patients
Variable Number 
of patients
RAC3 expression (qPCR) Fisher’s (P)
< 1 10–100 > 100
Normal tissue 3a 3 (100)
 Gender 0.5055
  Male 5 2 (40.0) 2 (40.0) 1 (20.0)
  Female 9 1 (11.0) 6 (66.7) 2 (22.2)
 Differentiation 0.5941
  Well 1 0 (0) 1 (100) 0 (0)
  Moderate 11 3 (27.3) 7 (63.6) 1 (9.1)
  Poor 2 0 (0) 0 (0) 2 (100)
 Tumor status 0.4660
  T1 2 1 (50.0) 1 (50.0) 0 (0)
  T2 0 0 (0) 0 (0) 0 (0)
  T3 10 2 (20.0) 6 (60.0) 2 (20.0)
  T4 2 0 (0) 1 (50.0) 1 (50.0)
 Nodal status 0.1280
  N0 9 3 (33.3) 4 (44.4) 2 (22.2)
  N1–2 5 0 (0) 4 (80.0) 1 (20.0)
 Metastasis status 1.000
  M0 12 3 (25.0) 6 (50.0) 3 (25.0)
  M1 2 0 (0) 2 (100) 0 (0)
 Clinical stage 0.1923
  I + II 7 3 (42.9) 4 (57.1) 0 (0)
  III + IV 7 0 (0) 4 (57.1) 3 (42.9)
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developed in our laboratory and cloned into the HuSH 
plasmid (OriGeneTechnologies, USA), shRAC3 sequence: 
GCTGCTAAGTCATCACTTCCGACAACAGA or 
shRAC3 (2) sequence: CCACATTGCCTCTTCGGTCTA 
ATAGCATA (data not shown) [28]. LoVo cells were trans-
fected with a plasmid expressing full-length cDNA of 
RAC3 or with empty vector (control). HCT 116 and LoVo 
cells were transfected using Lipofectamine 2000 (Invitro-
gen Corp., USA) according to the manufacturer’s proto-
col. Three days after transfection, the cells were incubated 
in selection medium containing 0.5  μg/ml Puromycin 
(HCT 116) or 0.5  mg/ml Geneticin (LoVo) (Invitro-
gen Corp., USA). After 14 days of selection, protein and 
mRNA expression were analyzed by immunoblotting and 
quantitative Real Time PCR (qPCR).
In reporter assays, HCT 116 control and shRAC3 cells 
were transfected with the reporter plasmid containing 
the NF-κB consensus binding sequence (κB-Luc) plus 
RSV-β-Gal as it was previously described [29].
Primers and qPCR
Total RNA was extracted using TRIzol reagent (Inv-
itrogen Corp., USA) and was employed to gener-
ate cDNA using Superscript III RT (Invitrogen Corp., 
USA) and an oligo(dT) primer. qPCR was performed 
using  LightCycler® 480 SYBR Green I Master (Roche, 
USA) according to the manufacturer’s protocol. For 
gene expression analysis, qPCR was performed by 
using sequence-specific primers for: RAC3 forward 
5′-AAGTGAAGAGGGATCTGGA-3′ and reverse 
5′-CAGATGACTACCATTTGAGG-3′, CD39 forward 
5′-AGCAGCTGAAATATGCTGGC-3′ and reverse 
5′-GAGACAGTATCTGCCGAAGTCC-3′.
For all analysis, GAPDH forward 5′-TCTCCTCTGA 
CTTCAACAGC-3′ and reverse 5′-GTTGTCATACCAGG 
AAATGA-3′ was used as an internal control.
Viability assays
Colorectal cancer cells lines were plated in 96-well flat 
bottom plates at a density of 8000 cells/well in 100 μl of 
medium. After 24 h, cells were stimulated with 5-fluoro-
uracil (FUra 0–150  μM) or oxaliplatin (Oxa 0–50  μM). 
Cells were fixed at specific time points and the cell via-
bility was determined by staining with 0.5% crystal vio-
let. Absorbance of surviving stained cells was measured 
at 570  nm. The percentage of surviving cells was deter-
mined with respect to basal conditions (without any 
treatment).
Half maximal inhibitory concentration 50  (IC50) val-
ues were calculated with GraphPad Prism software 
(GraphPad Software Inc., USA) using the sigmoidal 
dose–response function. Assays were carried out in 
triplicate and at least three independent experiments 
were conducted.
Western blot analysis
HT-29, LoVo wt, control or RAC3, HCT 116 wt, con-
trol and shRAC3 cells were harvested and lysed in RIPA 
buffer with protease inhibitors [29]. Then, cell lysates 
were separated via 6% SDS-PAGE and transferred to 
nitrocellulose membrane. The membranes were blocked 
in 10% skim milk and incubated with anti-RAC3 (Santa 
Cruz Biotechnology, USA).
For apoptosis experiments, cells were stimulated with 
FUra (3.5 μM) or Oxa (0.4 μM) for 6 or 24 h. For West-
ern blot of LC3II/I, cells were pre-incubated with 10 μg/
ml E64D and pepstatin A lysosomal protease inhibitors, 
before incubation with FUra (3.5  μM) or Oxa (0.4  μM) 
for 90  min. Then, cells were lysed as described before. 
Samples were separated by 10 or 15% SDS-PAGE and 
electro-transferred to nitrocellulose membranes. Mem-
branes were blocked in 10% skim milk and incubated 
with anti-pro-Caspase 3, Beclin 1 and LC3 antibodies.
The anti-Tubulin antibody was used as an internal con-
trol (Santa Cruz Biotechnology, USA) in all the assays.
Subsequently, all membranes were incubated for 1  h 
with horseradish peroxidase-conjugated secondary anti-
body, and the specific bands were visualized by autora-
diography using the chemiluminescence luminol reagent 
(Santa Cruz Biotechnology, USA).
Microscopy and immunofluorescence assays
HT-29, LoVo wt, control or RAC3, HCT 116 wt, con-
trol and shRAC3 cells were seeded in 24-well plates on 
12 mm glass coverslips. After 24 h, cells were stimulated 
with FUra (3.5 μM) or Oxa (0.4 μM) for 1, 6 or 24 h. For 
acetylated proteins assays, cells were pre-treated with a 
deacetylase inhibitor, Trichostatin A (0.4  μM TSA) and 
after 30 min stimulated with 0.4 μM Oxa or 3.5 μM FUra 
for 6 or 24 h.
For immunofluorescence assays the cells were fixed 
with 3% formaldehyde and 0.02% glutaraldehyde for 
15  min. Incubation with primary antibody against Lys-
acetylated (Cell Signaling Technology, Danvers, MA, 
USA) were performed 1  h room temperature in PBS 
with 10% FBS. Then, cells were washed with PBS, incu-
bated with a TRITC-labeled secondary antibody for 1 h, 
washed with PBS, mounted on glass slides with PBS/
Glycerol 1:1 solution.
Some cultures were stained with ethidium bromide 
(EtBr) and the morphology of death and surviving cells 
was observed by fluorescent microscopy. Ethidium bro-
mide only enters into non-viable cells and stains chroma-
tin with dark orange color [30].
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Autophagy induction was monitored by monodancyl 
cadaverine (MDC) staining and the percentage of cells 
showing an aggregated stain was determined by count-
ing a minimum of 100 cells per slide using fluorescence 
microscopy.
For all the assays cells were analyzed with an Olympus 
BX51 fluorescent microscope and 100 cells per field were 
counted. Images were taken with a digital camera and 
analyzed with NIH-ImageJ software.
Analysis of Gene Expression Omnibus (GEO)
To compare the RAC3 expression levels between meta-
static and primary lesions, in patients sensitive or not to 
Folic acid-5-fluorouracil and oxaliplatin treatment (FOL-
FOX), we used values obtained from GSE28702 data 
bank, platform GPL570 Affymetrix (Santa Clara, CA, 
USA) [31].
Luciferase assays
HCT 116 cells were plated in 24-well plates  24  h prior 
to transfection at a density of 250,000  cells/well. Cells 
were transiently transfected with a total of 0.5 μg of DNA 
(including 75  ng of κB-luc and 50  ng RSV-β Gal vec-
tors) using Lipofectamine 2000 protocol as previously 
reported [29]. The medium was replaced after 5 and 24 h 
later cells were pre-incubated with NF-κB inhibitor Sul-
fasalazine (SSZ 0.5  mM) for 30  min before stimulation 
with 3.5 μM FUra or 0.4 μM Oxa.
The assays for luciferase and β-galactosidase activity 
were performed after 24 h of treatment using the appro-
priate substrates in accordance with the manufacturer’s 
protocols (Promega corp.). To achieve transfections with 
a constant amount of DNA, appropriate amounts of 
empty vector (pRC3.1) were added to each well.
Statistical analysis
At least three independent experiments were carried out 
in all cases. Results were expressed as the mean  ±  SD. 
The significance of differences between experimental 
conditions was determined using ANOVA and the Tukey 
Multiple Comparisons Test for paired observations and 
a p  <  0.01 was considered statistically significant. For 
patients, differences in a given variable between groups 
were assessed using Fisher’s exact test and a p < 0.05 was 
considered statistically significant.
Results
RAC3 expression levels in CRC patients
Firstly, we investigated the RAC3 expression levels in 
patients with colorectal cancer (CRC). Afterwards, the 
RAC3 mRNA expression was evaluated by qPCR assays 
in 17 exploratory biopsies, 14 of which were confirmed 
by pathological examination as CRC and 3 were normal 
tissues. RAC3 was found overexpressed in 11 (78%) of 
the 14 CRC biopsies and by immunohistochemical stain-
ing it was determined that the expression was mainly 
cytoplasmic (Table 1 and Fig. 1a). RAC3 expression was 
substantially higher in CRC than in normal colon tissue 
samples (p < 0.0294), whereas in studies that included a 
greater number of patients (n = 85), overexpression was 
observed in 35% of the samples [25]. Although a corre-
lation between the clinical stage and the overexpression 
of RAC3 could be occurring, this hypothesis requires to 
be validated in larger cohorts of patients (Table  1 and 
Fig. 1b).
Then, we investigated RAC3 expression levels in meta-
static and primary lesions from patients sensitive or not 
to FOLFOX (Folic acid-5-fluorouracil and oxaliplatin) 
treatment. We analyzed the DataSets records in the Gene 
Expression Omnibus (GEO) repository from GSE28702 
data bank, platform GPL570 Affymetrix [31]. We found 
that patients who do not respond to FOLFOX treatment 
have higher coactivator expression levels than those 
patients that respond to treatment, being this difference 
significantly greater in metastatic lesions (Fig. 1c).
These results suggest that RAC3 could be probably con-
sidered as a predictive marker for CRC chemosensitivity.
(See figure on next page.) 
Fig. 1 RAC3 acts as a predictive marker for CRC prognosis and chemotherapeutic response: a representative RAC3 Immunohistochemistry in 
normal colorectal and CRC tissues. b The RAC3 expression levels in normal colorectal tissues and CRC tissues at different pathological stages were 
determined by qPCR and normalized with GAPDH mRNA. c The RAC3 expression levels are compared between metastatic and primary lesion 
in patients sensitive or not to FOLFOX treatment (Folic acid-5-fluorouracil and oxaliplatin). The diagram bars show the average ± S.D. of mRNA 
expression log-transformed values from GSE28702 data bank, platform GPL570 Affymetrix (Santa Clara, CA, USA) *p < 0.01 respect to FOLFOX non-
responder in Metastatic lesion. d RAC3 expression levels in three CRC cell lines are compared with normal colorectal and CRC tissues. The diagram 
bars correspond to average ± S.D. of RAC3 mRNA expression obtained by qPCR and normalized to GAPDH mRNA, *p < 0.001 respect to normal 
tissue and **p < 0.0001 respect to normal tissue and LoVo cell line. e Western blot was performed to determine the protein levels of RAC3 in the 
three CRC cell lines. Relative densitometry units (RDU) correspond to the average of densitometry units respect to Tubulin expression, obtained in 
three independent experiments. f, g Cell viability was determined by crystal violet staining and  IC50 doses were calculated with GraphPad software. 
CRC cells were treated with FUra (0–150 μM) for 72 h (f) or Oxa (0–50 μM) for 24 h (g) p < 0.001  IC50 LoVo respect to HCT 116 to FUra or respect to 
HCT116 and HT-29 to Oxa
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RAC3 expression levels in different CRC cell lines determine 
its sensitivity to chemotherapeutic drugs
5-Fluorouracil (FUra) and oxaliplatin (Oxa) are antime-
tabolite drugs that are widely used for cancer treatment, 
particularly for CRC [32]. Despite the increased under-
standing of the mechanism of action of these drugs, 
resistance to both of them remains as a significant limita-
tion for its clinical use.
To explore the potential role of RAC3 in CRC sensi-
tivity to drugs, we first investigated RAC3 expression 
in CRC cell lines (HT-29, HCT 116 and LoVo) by qPCR 
and western blot analysis. RAC3 expression levels were 
higher in HT-29 and HCT 116 cells than LoVo cells 
(Fig. 1d, e). Moreover, the RAC3 levels of this last cell line 
were similar to those expressed by normal colon tissues, 
as determined by qPCR (Fig.  1d), being not possible to 
confirm these results by western blot, due to the limiting 
amount of human colon normal tissues.
In view that these CRC cell lines express different levels 
of RAC3, they were employed as a model to validate the 
results obtained by GEO analysis. Thus, we investigated 
the sensitivity to FUra (0–150 μM) and Oxa (0–50 μM). 
Cell viability was determined by crystal violet staining 
and the  IC50 was calculated for each cell type (Fig. 1f, g). 
We found that the cell line HT-29 overexpressing RAC3 
did not respond to treatment with FUra in the concentra-
tion and time that we used. However, the LoVo cell line, 
whose RAC3 expression levels are lower, was more sensi-
tive to treatment with these drugs (Table 2).
In order to determine whether the sensitivity observed 
in the different CRC lines could be dependent of the 
RAC3 expression levels, the HCT116 cell line was trans-
fected with a plasmid containing the shRNA sequence for 
RAC3 (shRAC3) that we have previously used in other 
published works, having a good efficiency and specific-
ity [28] or scramble sequence (control). Concerning the 
LoVo cells, that naturally express low RAC3 levels, they 
were transfected with aRAC3 expression vector or the 
empty vector (control) [28]. The efficiency of knockdown 
or overexpression was validated by western blot and 
qPCR (Fig. 2a–d).
We found that HCT 116 shRAC3 displayed a signifi-
cantly decreased viability in response to chemotherapeu-
tic drugs comparing to the control (Fig.  2e, g, Table  2). 
However, LoVo cells became more resistant to death-
induced by both chemotherapeutic drugs when RAC3 is 
overexpressed (Fig. 2f, h, Table 2). Interestingly, the Oxa 
stimulation of this cell line follows a particular concen-
tration-dependent response whose maximal prolifera-
tion inhibitory effect saturates reaching values that are 
below 40% in LoVo wt. However, although RAC3 over-
expression significantly decreased the  IC50, the curve of 
biological response was modified, reaching higher maxi-
mal values of cell death. This unexpected result for Oxa 
concentrations higher than 0.4  μM could be probably 
explained regarding the anti-senescent and proliferative 
stimulating role of RAC3 [33], which perhaps could be 
increasing the number of cells capable to respond to Oxa 
stimulation. Therefore, taking together all these results 
clearly demonstrate that the expression levels of RAC3 
may influence the sensitivity to chemotherapeutic drugs, 
increasing the chemoresistance when is overexpressed.
The decrease of RAC3 expression levels promotes 
apoptosis induced by FUra and Oxa
We have previously reported that overexpression of 
RAC3 inhibits apoptosis and this is one of the mecha-
nisms involved in resistance to treatment with chemo-
therapeutic agents [26, 27]. Therefore, we decided to 
study whether RAC3 would be affecting the sensitivity 
to these chemotherapeutics via the inhibition of apopto-
sis. HCT 116, LoVo and HT-29 cell lines were stimulated 
with a drug concentration close to the  IC50 and regard-
ing the upper and lower limit of the  CI95 for each cell line 
(Table 2).
As shown in Fig.  3a, b and in agreement with that 
observed in assays of cell proliferation, HT-29 cells 
were not-sensitive to apoptosis induced by both drugs. 
Table 2 Cytotoxic effects of 5-fluorouracil and oxaliplatin against colorectal cancer cell lines
Values represent results from at least three independent experiments
FUra Oxa
IC50 μM  (CI95) % top inhibition  (CI95) IC50 μM  (CI95) % top inhibition  (CI95)
HT-29 N.A. N.A. 0.8 (0.6–1.0) 34% (31–36)
LoVo 0.6 (0.4–0.9) 80% (75–86) 0.05 (0.02–0.1) 33% (29–36)
LoVo control 0.6 (0.4–0.7) 82% (79–84) 0.04 (0.01–0.1) 30% (26–34)
LoVo RAC3 2.0 (1.4–2.8) 48% (45–51) 0.4 (0.25–0.6) 50% (46–53)
HCT 116 wt 4.5 (3.9–5.1) 75% (71–78) 0.6 (0.4–0.9) 36% (30–38)
HCT 116 control 4.2 (3.3–5.3) 78% (74–81) 0.6 (0.45–0.85) 42% (38–45)
HCT 116 shRAC3 2.4 (2.1–3.0) 88% (84–91) 0.17 (0.05–0.5) 52% (43–61)
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However, LoVo cells were sensitive to Oxa and FUra-
induced apoptosis after 24  h of treatment, showing a 
significant increase in the percentage of cells positive for 
Ethidium Bromide (EtBr) (Fig. 3a, b). In the case of HCT 
116, only Oxa was able to induce apoptosis after 24 h.
Therefore, using the cells where apoptosis could be 
induced, we then investigated if this process could be 
affected by different RAC3 expression levels. Thus, 
we found that sensitivity to apoptosis of HCT 116 cells 
was significantly enhanced when RAC3 was knocked 
(shRAC3), showing a significant increase of positive 
apoptotic cells after 6  h of treatment, earlier than HCT 
116 control cells (Fig. 3c, d). Moreover, they became sen-
sitive to FUra-induced apoptosis.
In agreement with previous evidences, the active Cas-
pase 3 is an indicator of late apoptosis, while Beclin 1 is 
one of its targets. In addition, the cleavage products of 
this last protein inhibit autophagy but promote apopto-
sis [34]. Then, we analyzed the modulation of these pro-
teins by drugs stimulation in cells overexpressing or not 
RAC3. We found a significant reduction of pro-Caspase 
3, accompanied by the increased Beclin 1 cleavage in cells 
with low RAC3 expression, after treatment with FUra for 
24 h (RDU 1.5 vs 1.1) and Oxa at 6 (1.4 vs 1.2) or 24 h (1.5 
vs 1.2), (Fig. 3e).
In order to confirm these results we then investigated 
if LoVo cells, which naturally express low levels of RAC3 
and are sensitive to apoptosis induced by both drugs, may 
be affected by RAC3 overexpression. Therefore, we ana-
lyzed apoptosis in control and RAC3 overexpressing cells 
performing the same experiments as in HCT 116 cells. 
As shown in Fig. 3f, g, when LoVo cells overexpress RAC3 
they became completely resistant to both drugs, at least 
in the concentrations that were assayed. As expected, no 
cleavage of pro-Caspase 3 and Beclin 1 could be detected 
(Fig. 3h).
Therefore, our results suggest that expression levels 
of RAC3 could be affecting the sensitivity to apoptosis-
induced by chemotherapeutic drugs; however, autophagy 
could be also involved.
The increase of autophagy under low RAC3 expression 
levels maximizes the FUra treatment
Recent studies suggest that autophagy could be playing 
an important role in cancer development, determining 
the response to anticancer therapy. However, the role 
of autophagy in these processes is not at all clear, thus, 
depending on the circumstances, it may have diametri-
cally opposite consequences for the tumor [35].
Many anticancer agents have been reported to induce 
autophagy, supporting the idea that autophagic cell death 
may be an important mechanism for tumor cell killing by 
these agents [36].
We have previously demonstrated that RAC3 overex-
pression inhibits autophagy [28]. Therefore, in order to 
investigate whether RAC3 could be affecting autophagy 
CRC cell lines, we first investigated if these drugs are 
capable to induce this response.
Thus, cell lines were stimulated with FUra (3.5 μM) or 
Oxa (0.4 μM) for 1 or 6 h. The Fig. 4a, b show that both 
drugs may induce autophagy in all the cell lines, includ-
ing HT-29 cells which are resistant to apoptosis. In LoVo 
cells, the basal autophagy was naturally high, suggesting 
it could be a surviving strategy as previously described 
[28]. In the case of HT29 cells, although both drugs 
were unable to induce cell death (Fig.  3b), they trigged 
autophagy, suggesting it plays a surviving role, as in LoVo 
cells [28].
Being these cells sensitive to autophagy induced by 
both drugs, we then analyzed how could be affected by 
RAC3.
We found that autophagy started earlier (1 vs 6 h) and 
was significantly higher in HCT 116 shRAC3 than in 
control HCT 116 (Fig.  4c–e). In the case of LoVo cells, 
the RAC3 overexpression significantly inhibited the 
autophagy induced by both drugs, as determined by 
MDC staining and LC3 detection (Fig. 4f–h).
Hence, in agreement with these results, we found that 
FUra was a better inducer of autophagy than apoptosis in 
cells that overexpress RAC3, suggesting this is the main 
mechanism by which induces cell death. However, the 
anti-tumoral effect of Oxa shows to be mainly mediated 
through apoptosis.
The sensitivity to both drugs was significantly increased 
under low expression levels of RAC3, showing a greater 
apoptosis and autophagy which were evidenced earlier 
than in cells overexpressing RAC3.
The oxaliplatin and 5‑fluorouracil—induced decrease 
of acetylated proteins is enhanced in cells expressing low 
levels of RAC3
Accumulating evidence suggests that the long-term suc-
cess of anti-neoplastic therapies is largely determined 
by their capacity to reinstate anticancer immunosurveil-
lance [37]. One of the requisites of immunogenic chemo-
therapy is the induction of autophagy [38]. This process 
allows the optimal lysosomal exocytosis of ATP from 
dying tumor cells [39] and avoids the up regulation of the 
immunosuppressive ecto-ATPase CD39 [40].
In view that reduction in lysine acetylation of cellular 
proteins could be a good inducer of autophagy and ATP 
exocytosis [40], we investigated the effect of FUra and 
Oxa over the degree of protein acetylation. Although 
HCT 116 and HT-29 cell lines have similar basal levels 
of acetylated proteins, we found that acetylation was sig-
nificantly inhibited by drugs stimulation only in HCT116 
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(Fig.  5a, b), Interestingly, this cell line is which better 
respond to autophagy induction (Fig. 4a, b).
Concerning LoVo cells, which naturally express low 
levels of RAC3, the basal acetylation was lower than in 
the other cell lines and no modulation by drugs stimula-
tion was observed (Fig. 5a, b).
When we analyzed the effect of RAC3 knocking in 
HCT 116, we found that both basal and drug-induced 
acetylation at 24 h were significantly inhibited respect to 
HCT116 control cells (Fig. 5c, d).
In the case of LoVo cells, RAC3 overexpression induced 
a significant increase of basal acetylation that could not 
be inhibited by anyone of the drugs (Fig. 5e, f ).
Taken together all these results, we may conclude that 
high RAC3 expression contributes to the increased basal 
levels of protein acetylation, which could be compatible 
with its intrinsic histone acetylase activity [16], although 
additional substrates could not be excluded. However, 
different levels of RAC3 expression do not modify the 
sensitivity to drugs-induced acetylation. Therefore, 
despite acetylation inhibition could be involved in 
autophagy induction, our results demonstrate that this 
is not the mechanism by which RAC3 may modulate the 
sensitivity to drugs-induced autophagy.
Despite pre-mortem autophagy is not essential for 
chemotherapy-elicited cancer cell death to occur [41], 
it is indispensable for immunogenic cell death (ICD) 
through the ATP release into the extracellular space 
where it serves as a chemotactic factor to attract antigen-
presenting cells into the neighbor microenvironment of 
dying cells [38, 42]. This effect is achieved by the capac-
ity of extracellular ATP to act on purinergic receptors in 
the surface of immature dendritic cell precursors and T 
cells [42]. The suppression of autophagy in tumor cells 
or CD39 overexpression by tumoral cells, blockade the 
capacity of chemotherapy to stimulate the invasion of 
tumors by antigen-presenting cells [42].
Since cells overexpressing RAC3 have a low drug-
induced autophagy, we analyzed the CD39 expression 
in cells having high and low RAC3 levels. We found that 
without stimulation, those cells having low RAC3 (LoVo 
control and HCT 116 shRAC3) show a lower expres-
sion of CD39 than cells with high coactivator expression 
(HT-29, LoVo RAC3 and HCT 116 control) (Fig.  5g). 
Then, we investigated the effect of Oxa and FUra over 
HCT 116 and LoVo. We found that Oxa induced a signifi-
cant decrease of CD39 in control and shRAC3 HCT116 
although not FUra effect was observed in shRAC3 
(Fig.  5h). In the case of LoVo cells, both drugs induced 
the CD39 inhibition (Fig. 5h).
Therefore, although RAC3 did not affect the natu-
ral biological action of these drugs, cells expressing 
low RAC3 were more sensitive to chemotherapeutics-
induced autophagy and express lower levels of CD39.
Chemoresistance under high RAC3 expression levels could 
be partially mediated through the enhanced NF‑κB activity
We have previously demonstrated that RAC3 is a NF-κB 
coactivator [23] that exerts an anti-apoptotic and anti-
autophagic role when is overexpressed, not only enhanc-
ing the expression of NF-κB target genes, but also 
through additional cytoplasmic actions [27, 28]. More-
over, the overexpression of a mutated form of RAC3 
lacking the tag nuclear signal, which avoids its nuclear 
translocation, also exerts an anti-apoptotic role [28].
Therefore, in view that RAC3 is mainly localized in 
the cytoplasmic compartment of CRC, we investigated 
if at least part of the chemoresistance to FUra and Oxa-
induced cell death could be mediated through NF-κB 
activity.
First, we investigated if FUra and Oxa could induce 
the NF-κB activation at the concentrations that were 
assayed in all the experiments. We found that both 
drugs were capable to activate NF-κB in control cells, as 
expected for several stress signals or apoptosis inducers 
[30]. This activity was significantly inhibited by the IKK 
inhibitor SSZ showing values similar to basal conditions 
(Fig. 6a). However, the drugs-induced NF-κB activity was 
(See figure on next page.) 
Fig. 5 Autophagy induction by FUra and OXA induces a decrease in protein acetylation in HCT 116 cells: a, c and e Cells were pre-treated with a 
deacetylase inhibitor TSA (0.4 μM) for 30 min and then, stimulated with FUra (3.5 μM) or Oxa (0.4 μM) for 6 or 24 h. The arrows show the positive 
acetylation detected by immunofluorescence using an anti-Lysine acetylated antibody and an antibody anti-mouse coupled to Rodamine. A cell 
detail of the 10 × magnification is shown in the square. b, d and f Diagram bars correspond to percentage of acetylated protein per field (at least 10 
fields per sample). Statistical analysis ANOVA and Tukey post-test n = 3 were performed. b *p < 0.001 LoVo TSA respect to HT-29 and HCT 116 TSA, 
HCT 116 treated respect to HCT 116 TSA, d *p < 0.01 HCT 116 control TSA plus 3.5 μM FUra at 24 h respect to HCT 116 control TSA, **p < 0.001 HCT 
116 control TSA plus FUra or Oxa at 6 h respect HCT 116 control TSA and HCT 116 shRAC3 TSA respect HCT 116 control TSA and f *p < 0.001 LoVo 
RAC3 with TSA respect to LoVo control TSA. g Expression levels of CD39 in CRC cell lines. The diagram bars show the average ± S.D. of CD39 expres-
sion normalized to GAPDH from three independent experiments, *p < 0.001 HCT 116 shRAC3 and LoVo control respect to HCT 116 control and 
Lovo RAC3 respect to LoVo control. h The diagram bars show the average ± S.D. of CD39 expression normalized to GAPDH from three independent 
experiments, *p < 0.001 HCT 116 shRAC3 basal respect to HCT 116 control basal and **p < 0.01 cells treated with 0.4 μM Oxa respect to HCT 116 
control basal or HCT 116 shRAC3 basal
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significantly lower in shRAC3 than in control cells, as 
expected, being RAC3 a required NF-κB coactivator [23]. 
Therefore, no effect of SSZ could be detected over drugs-
induced NF-κB activity in shRAC3 cells (Fig. 6a).
Then, using the same SSZ concentration, we investi-
gated its effect over drugs-induced apoptosis. As shown 
in Fig.  6b, c, SSZ significantly increased the FUra and 
Oxa-induced apoptosis in both control and shRAC3 
HCT 116. Although the increased cell death in control 
HCT 116 was almost 100%, a lower effect but still sig-
nificant was observed in HCT 116 shRAC3. Therefore, 
most of the resistance of RAC3-overexpressing cells to 
chemotherapeutics-induced apoptosis could be mainly 
mediated through an increased NF-κB activity. However, 
our results also suggest that additional signals not related 
to this transcription factor but at least dependent of IKK 
activity could be involved.
Discussion
Previous studies demonstrated that RAC3 is a critical 
predictor of cancer prognosis in different cancer types 
[43, 44]. The gene for this molecule was reported to be 
amplified in 2–10% of human breast tumors and the pro-
tein overexpressed in 30–60% of tumors, suggesting that 
RAC3 provides a growth advantage for breast cancer cells 
[44]. In CRC studies, a copy number gain of RAC3 was 
detected in 27.5% and it is overexpressed in 35% CRC 
samples correlating with tumor progression [25, 45]. 
Despite all these evidences, the role of RAC3 in CRC 
chemoresistance is still unknown.
In the present study, we reported new findings compel-
ling evidence that RAC3 overexpression in CRC cell lines 
decreases the sensitivity to chemotherapeutic drugs and 
the mechanism involves the inhibition of apoptosis and 
autophagy induced by these agents.
In this work, we found that normal tissues express low 
levels of RAC3, but CRC samples shown an overexpres-
sion of this molecule, as expected, while its localization 
was mainly cytoplasmic. This last observation could 
be particularly interesting concerning the mechanisms 
by which RAC3 may contribute to CRC development. 
Indeed, it is in agreement with our previous works dem-
onstrating that besides its nuclear role as a coactivator, 
enhancing the NF-κB activity and increasing the anti-
apoptotic genes expression, RAC3 has a cytoplasmic 
role, regulating kinase activity, interacting with cytoskel-
etal proteins, delaying the AIF nuclear translocation and 
inhibiting apoptosis [27].
Concerning the RAC3 anti-autophagic role, we have 
previously demonstrated that part of the mechanism 
involves NF-κB activation. However, the overexpres-
sion of a truncated form of RAC3 that lacks the signal 
for nuclear translocation also exerts an anti-autophagic 
role, suggesting that cytoplasmic actions of RAC3 may 
contribute to this activity [28]. Therefore, RAC3 is a very 
particular molecule which has the ability to modulate 
multiple biological responses through several not related 
mechanisms in different cellular compartments. Thus, 
in the nucleus it can modify the transcriptional activ-
ity of steroid nuclear receptors and transcription factors 
through its own histone acetylase activity, but also by 
recruitment of other molecules, changing the expression 
pattern of a wide amount of target genes [16]. In addi-
tion, in the cytoplasm, RAC3 may be associated to sev-
eral proteins modulating its activity [27]. Although no 
cytoplasmic RAC3 acetylase substrates have been identi-
fied to date, this possibility should not be excluded and 
deserves to be investigated, regarding the RAC3 cyto-
plasmic abundance in some tumors, as well as our own 
results concerning the increase of total proteins acetyla-
tion when RAC3 is overexpressed.
Afterwards, the predominantly cytoplasmic localiza-
tion observed in CRC tissues could be determinant in 
chemotherapeutic response and probably related to the 
molecular mechanisms of both apoptosis and autophagy 
signaling pathways where RAC3 exerts the inhibitory 
effect. However, our results demonstrate that despite its 
cytoplasmic localization, most of the anti-apoptotic effect 
under chemotherapeutics treatment could be medi-
ated through an enhanced NF-κB activity, as a nuclear 
(See figure on previous page.) 
Fig. 6 NF-κB activity is partially involved in the chemoresistance induced by high RAC3 expression levels: a HCT 116 control or shRAC3 cells were 
co-transfected with κB-Luc reporter plasmid plus RSV-β Gal. Cells were pre-stimulated for 30 min with 0.5 mM SSZ or DMSO, prior to treatment with 
3.5 μM FUra or 0.4 μM Oxa for 24 h. The diagram bars correspond to the average ± S.D. of relative light units normalized with the corresponding 
β-galactosidase values, *p < 0.01 HCT 116 shRAC3 treated with 3.5 μM FUra respect to HCT 116 shRAC3 basal and ***p < 0.001 HCT 116 control 
treated with drugs respect to HCT 116 control basal, HCT 116 control treated with FUra or Oxa plus SSZ respect to HCT 116 control without SSZ and 
HCT 116 shRAC3 respect to HCT 116 control. b, c HCT 116 cell lines were pre-stimulated for 30 min with 0.5 mM SSZ and then the cells were treated 
for 6 h with 3.5 μM FUra or 0.4 μM Oxa. b Representative microphotography (200×) of apoptotic Ethidium Bromide (EtBr) stained cells after 6 h of 
treatment and c Diagram bars correspond to the percentage of EtBr positive cells per field (at least 10 fields per sample), *p < 0.05 HCT 116 control 
or shRAC3 FUra plus SSZ respect to HCT 116 treated with FUra and HCT 116 shRAC3 Oxa plus SSZ respect to shRAC3 Oxa, **p < 0.01 HCT 116 control 
FUra + SSZ respect to HCT 116 control basal and HCT 116 shRAC3 FUra respect to HCT 116 hsRAC3 basal, ***p < 0.001 HCT 116 control Oxa + SSZ 
respect to HCT 116 control basal and Oxa, HCT 116 shRAC3 FUra + SSZ or Oxa + SSZ respect to HCT 116 shRAC3 treated with FUra or Oxa, respec-
tively
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receptor coactivator. However, additional signals, nuclear 
or cytoplasmic, could not be excluded in the RAC3-
induced anti-apoptotic and anti-autophagic activity.
In a previous work performed in primary cutaneous 
melanoma samples, the authors described RAC3 as a 
prognostic marker for the prediction of survival asso-
ciated with melanoma [46], while in breast cancer the 
RAC3 overexpression was considered as a predictor of 
resistance to Tamoxifen treatment [44]. In this regard, in 
this work, through the in silico analysis we demonstrate a 
correlation between the response to FOLFOX treatment 
and the RAC3 expression levels. Therefore, our findings 
in CRC are in agreement with other previous works, sup-
porting that levels of RAC3 expression could have a pos-
sible predictive role concerning chemoresistance.
When we analyzed the expression levels of RAC3 in 
patients of the IDIM hospital population and its corre-
lation with the tumor stage, the results obtained show a 
tendency similar to that reported by other authors [25]. 
Because our work involves exclusively an aged popula-
tion, it is particularly interesting, given that a higher CRC 
incidence in patients over 65 has been described in last 
recent years [47]. However, preventive care in this pop-
ulation has only been addressed by a limited number 
of guidelines and cancer screening in the elderly (those 
greater than 75 years of age) has been controversial [47, 
48].
The lifetime risk of colorectal cancer is  ~  5% with an 
incidence in the population over 75 years at about 40–50 
per 100,000 persons. However, the incidence falls off to 
15–20 per 100,000 in persons 60–65 years [2]. Therefore, 
although we have not performed a comparative study 
between young and elderly patients, our findings con-
tribute to increase the knowledge about molecules to be 
studied in CRC, not only as possible predictive mark-
ers of chemoresistance, but also as targets in order to 
improve anticancer therapies.
As discussed above, although the inhibitory effects of 
RAC3 overexpression on the action of chemotherapeu-
tic drugs have been investigated, most of these studies 
are restricted to its role as a coactivator in the nucleus. 
We have previously demonstrated that RAC3-overex-
pressing cells are resistant to apoptosis and furthermore, 
RAC3-knocked K562 leukemic cell line becomes sen-
sitive to treatment with flavopiridol [26, 27]. Indeed, in 
this work, we demonstrated for the first time that while 
RAC3 overexpression inhibits 5-fluorouracil and oxalipl-
atin-induced apoptosis, its knocking turns CRC cells into 
sensitive.
Several works support a dual role for autophagy in 
tumor development: Inducing cell death, or exerting a 
surviving role [49]. This last role is in agreement with the 
elevated basal autophagy levels usually found in tumoral 
cells, like pancreatic cancer [50] as well as the surviving 
under stress conditions like hypoxia and starving [51, 52], 
a common situation to which cancer cells are exposed 
before the angiogenesis, migration and invasion. How-
ever, it is also known that an exacerbated autophagy 
could lead to cell death, and moreover, this could be 
the mechanism by which some chemotherapeutic drugs 
attack the tumoral cells [36].
Despite the controversial role of autophagy in cancer 
development and tumor progression, recent studies dem-
onstrate that autophagy has a relevant function in chem-
otherapeutic efficiency by induction of ATP exocytosis, 
chemotaxis of dendritic cells and ICD induction [39]. In 
this work, we demonstrate that both 5-fluorouracil and 
oxaliplatin are able to induce autophagy more efficiently 
in cells that express low levels of RAC3 through at least, 
a diminished protein acetylation and CD39 down regu-
lation. Interestingly, both processes are involved in the 
capacity to stimulate the invasion of tumors by antigen-
presenting cells.
Conclusions
Taken all together these results, we demonstrate for the 
first time that RAC3 overexpression could be playing a 
critical role in CRC tumoral cells affecting the sensitiv-
ity to apoptosis and autophagy induced by chemothera-
peutic drugs. Moreover, concerning the mechanism, our 
results demonstrate that at least part of the chemore-
sistance due to RAC3 overexpression could be depend-
ent of its transcriptional activity as coactivator of NF-κB. 
However, in agreement with our results showing a strong 
RAC3 cytoplasmic localization in CRC cells, additional 
not-nuclear effects could not be excluded, being per-
haps an original and interesting point to be considered 
in order to design future improved therapies for CRC 
treatment.
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